Skip Navigation


JAC Advance Access originally published online on January 13, 2005
Journal of Antimicrobial Chemotherapy 2005 55(2):135-138; doi:10.1093/jac/dkh530
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/2/135    most recent
dkh530v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Balzarini, J.
Right arrow Articles by Pannecouque, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balzarini, J.
Right arrow Articles by Pannecouque, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.55 no.2 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Leading article

Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action

Jan Balzarini*, Miguel Stevens, Erik De Clercq, Dominique Schols and Christophe Pannecouque

Rega Institute for Medical Research, K. U. Leuven, B-3000 Leuven, Belgium

* Corresponding author. Tel: +32-16-337341; Fax: +32-16-337340; Email: jan.balzarini{at}rega.kuleuven.ac.be

Pyridine N-oxide derivatives represent a new class of anti-HIV compounds, for which some members exclusively act through inhibition of HIV-1 reverse transcriptase and thus characteristically behave as non-nucleoside reverse transcriptase inhibitors. Other members act, additionally or alternatively, at a post-integrational event in the replication cycle of HIV, that is, at the level of HIV gene expression. Repeated administration of one of the prototype compounds (JPL-32) to DBA/2 and hu-PBMC-SCID mice demonstrated, in the absence of any acute toxicity, protective activity against HIV-induced destruction of CD4 human T lymphocytes.

Keywords: NF-{kappa}B , reverse transcriptase , NNRTI;transcription inhibitors , HIV chemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. Balzarini, E. Keyaerts, L. Vijgen, F. Vandermeer, M. Stevens, E. De Clercq, H. Egberink, and M. Van Ranst
Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture
J. Antimicrob. Chemother., March 1, 2006; 57(3): 472 - 481.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.